<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725985</url>
  </required_header>
  <id_info>
    <org_study_id>28821</org_study_id>
    <nct_id>NCT00725985</nct_id>
  </id_info>
  <brief_title>Oral Cladribine in Early Multiple Sclerosis (MS)</brief_title>
  <acronym>ORACLE MS</acronym>
  <official_title>A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, clinical trial to assess the safety and efficacy of two doses of&#xD;
      oral cladribine versus placebo in participants who had a first clinical demyelinating event&#xD;
      (clinically isolated syndrome). Participants in either the cladribine or placebo group may&#xD;
      also enter treatment periods with open-label interferon-beta or open-label cladribine&#xD;
      depending upon the disease status. The primary objective of this study is to evaluate the&#xD;
      effect of two dosage regimens of oral cladribine versus placebo on the time to conversion to&#xD;
      multiple sclerosis (MS) (from randomization) according to the Poser criteria in participants&#xD;
      with first clinical demyelinating event at high risk of converting to MS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double blind, three-arm, placebo-controlled, multi-center trial to&#xD;
      evaluate the safety and efficacy of oral cladribine versus placebo in the treatment of&#xD;
      participants who have sustained a first clinical demyelinating event within 75 days prior to&#xD;
      the Screening. Participants must have a minimum of 2 clinically silent lesions on the&#xD;
      Screening magnetic resonance imaging (MRI).&#xD;
&#xD;
      The study will include a pre-study evaluation period (Screening period: between 10 and 28&#xD;
      days prior to the start of treatment with blinded study medication (oral cladribine or&#xD;
      placebo).&#xD;
&#xD;
      Depending upon the clinical course of their MS, participants will then proceed from the ITP&#xD;
      to either the Maintenance Treatment Period (with open-label interferon-beta treatment) or&#xD;
      LTFU period (with either open-label low-dose cladribine or no additional treatment (if no&#xD;
      progression to MS has been noted after the initial treatment period). The single primary&#xD;
      endpoint for the overall study, which will be determined during the ITP, is time to&#xD;
      conversion to MS (from randomization), according to the Poser criteria.&#xD;
&#xD;
      For every participants, eligibility for study enrollment and entry into each of the study&#xD;
      periods, and diagnosis of conversion to either McDonald MS or CDMS must be confirmed and&#xD;
      approved by a Sponsor appointed study Adjudication Committee.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 31, 2008</start_date>
  <completion_date type="Actual">April 30, 2012</completion_date>
  <primary_completion_date type="Actual">July 31, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS</measure>
    <time_frame>ITP: Baseline up to Week 96</time_frame>
    <description>CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to Multiple Sclerosis [MS]) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (&gt;=) 1 point if baseline EDSS was between &gt;= 1.0 and less than or equal to (=&lt;) 4.5; or &gt;= 1.5 points if baseline EDSS was 0, or &gt;= 0.5 if baseline EDSS &gt;= 5.0 over a period of at least 3 months. Kaplan-Meier estimates were provided for of the cumulative (cum.) percentage (%) of participants with CDMS over time. The probability of patients remaining event-free over time (from randomization) in each of the three treatment groups was displayed in the form of survival curves estimated using the non-parametric Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ITP: Time to Develop Multiple Sclerosis (MS) Conversion According to the Revised McDonald Criteria (2005) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With McDonald MS</measure>
    <time_frame>ITP: Baseline up to Week 96</time_frame>
    <description>The McDonald criteria use dissemination in time and space established by magnetic resonance imaging (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium enhanced (Gd+) lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions. Kaplan-Meier estimates were provided for the cum. percentage (%) of participants with McDonald MS over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITP: Number of Combined Unique Active (CUA) Lesions, New or Enlarging Time Constant 2 (T2) Lesions, and New or Persisting Time Constant 1 (T1) Gadolinium Enhanced (Gd+) Lesions Per Participant Per Scan</measure>
    <time_frame>ITP: Baseline up to Week 96</time_frame>
    <description>Number of CUA lesions, new or enlarging T2 lesions, and new or persisting T1 Gd+ lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLMP: Time to 3 Month Confirmed Expanded Disability Status Scale (EDSS) Progression From Randomization Represented by Kaplan-Meier Estimates of Probability of Disability Progression</measure>
    <time_frame>OLMP: Day 1, 90, 180, 270, 360, 450, 540, 630, 720 and 810</time_frame>
    <description>EDSS progression is based on a standardized neurological exam and focuses on symptoms that commonly occur in Multiple Sclerosis (MS). Overall scores ranges from 0.0 (normal) to 10.0 (death due to MS). A sustained progression on EDSS score was defined as an EDSS progression confirmed into two consecutive assessment. Probability of disability progression at different time points was estimated using Kaplan-Meier method on the time to disability progression defined as the time from randomization to first EDSS increase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Multiple Sclerosis (MS) According to the 2005 McDonald Criteria</measure>
    <time_frame>Time from Randomization up to 1217 days</time_frame>
    <description>The McDonald criteria use dissemination in time and space established by magnetic resonance imaging (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium enhanced (Gd+) lesion found on a repeat MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria</measure>
    <time_frame>Time from Randomization up to 1217 days</time_frame>
    <description>CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (&gt;=) 1 point if baseline EDSS was between &gt;= 1.0 and less than or equal to (=&lt;) 4.5; or &gt;= 1.5 points if baseline EDSS was 0, or &gt;= 0.5 if baseline EDSS &gt;= 5.0 over a period of at least 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria</measure>
    <time_frame>Time from Randomization up to 1217 days</time_frame>
    <description>CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (&gt;=) 1 point if baseline EDSS was between &gt;= 1.0 and less than or equal to (=&lt;) 4.5; or &gt;= 1.5 points if baseline EDSS was 0, or &gt;= 0.5 if baseline EDSS &gt;= 5.0 over a period of at least 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITP: Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) as Per Poser Criteria</measure>
    <time_frame>ITP: Baseline up to week 96</time_frame>
    <description>Clinically definite multiple sclerosis (CDMS) according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (&gt;=) 1 point if baseline EDSS was between &gt;= 1.0 and less than or equal to (=&lt;) 4.5; or &gt;= 1.5 points if baseline EDSS was 0, or &gt;= 0.5 if baseline EDSS &gt;= 5.0 over a period of at least 3 months. The percentage of participants who converted to CDMS are reported here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITP: Percentage of Participants Converting to McDonald Multiple Sclerosis (MS) (2005)</measure>
    <time_frame>ITP: Baseline up to week 96</time_frame>
    <description>Percentage of participants converting to mcDonald multiple sclerosis (2005) were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITP: Number of New or Persisting Gd-enhanced Lesions</measure>
    <time_frame>ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96</time_frame>
    <description>Number of new or persisting Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLMP: Number of New or Persisting Gd-enhanced Lesions</measure>
    <time_frame>OLMP: Baseline, Week 24, 48, 72 and 96</time_frame>
    <description>Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions</measure>
    <time_frame>LTFU: Baseline, Week 13, 24 and 36</time_frame>
    <description>Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions</measure>
    <time_frame>LTFU: Baseline, Week 13, 24, 36 and 48</time_frame>
    <description>Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITP: Number of New or Enlarging T2 Lesions</measure>
    <time_frame>ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96</time_frame>
    <description>Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLMP: Number of New or Enlarging T2 Lesions</measure>
    <time_frame>OLMP: Baseline, Week 24, 48, 72 and 96</time_frame>
    <description>Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Enlarging T2 Lesions</measure>
    <time_frame>LTFU: Baseline, Week 13, 24 and 36</time_frame>
    <description>Number of new or enlarging T2 Lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Enlarging T2 Lesions</measure>
    <time_frame>LTFU: Baseline, Week 13, 24, 36 and 48</time_frame>
    <description>Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions</measure>
    <time_frame>ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96</time_frame>
    <description>Number of CUA lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLMP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions</measure>
    <time_frame>OLMP: Baseline, Week 24, 48, 72 and 96</time_frame>
    <description>Number of combined unique active (CUA) lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions</measure>
    <time_frame>LTFU: Baseline, Week 13, 24 and 36</time_frame>
    <description>Number of CUA MRI lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions</measure>
    <time_frame>LTFU: Baseline, Week 13, 24, 36 and 48</time_frame>
    <description>Number of CUA lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITP: Change From Baseline in Volume of T1 Gd-Enhanced Lesions</measure>
    <time_frame>ITP: Baseline, Week 96</time_frame>
    <description>Change in volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLMP: Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions</measure>
    <time_frame>OLMP: Baseline, Week 24, 48, 72 and 96</time_frame>
    <description>Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions</measure>
    <time_frame>LTFU: Baseline, Week 13, 24 and 36</time_frame>
    <description>Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions</measure>
    <time_frame>LTFU: Baseline, Week 13, 24, 36 and 48</time_frame>
    <description>Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITP: Changes From Baseline in Volume of T2 Lesions</measure>
    <time_frame>ITP: Baseline, Week 48 and 96</time_frame>
    <description>Change in volume of T2 lesions from baseline was measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLMP: Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions</measure>
    <time_frame>OLMP: Baseline, Week 48 and 96</time_frame>
    <description>Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T2 Lesions</measure>
    <time_frame>LTFU: Baseline (Day 1)</time_frame>
    <description>Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITP: Number of T1 Hypointense Lesions</measure>
    <time_frame>ITP: Baseline, Week 48 and 96</time_frame>
    <description>Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLMP: Number of T1 Hypointense Lesions</measure>
    <time_frame>OLMP: Baseline, Week 48 and 96</time_frame>
    <description>Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of T1 Hypointense Lesions</measure>
    <time_frame>LTFU: Baseline (Day 1)</time_frame>
    <description>Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of T1 Hypointense Lesions</measure>
    <time_frame>LTFU: Baseline, Week 48</time_frame>
    <description>Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions</measure>
    <time_frame>ITP: Baseline up to Week 96</time_frame>
    <description>T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLMP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions</measure>
    <time_frame>OLMP: Baseline up to Week 96</time_frame>
    <description>T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions</measure>
    <time_frame>LTFU: Baseline up to Week 48</time_frame>
    <description>T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions</measure>
    <time_frame>Baseline up to Week 48</time_frame>
    <description>T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITP: Percentage of Participants With no New or Enlarging T2 Lesions</measure>
    <time_frame>ITP: Baseline up to Week 96</time_frame>
    <description>T2 lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or enlarging T2 lesions were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLMP: Percentage of Participants With no New or Enlarging T2 Lesions</measure>
    <time_frame>OLMP: Baseline up to 96</time_frame>
    <description>T2 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or enlarging T2 Lesions were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions</measure>
    <time_frame>Baseline up to Week 48</time_frame>
    <description>Enlarging T2 Lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no New or Enlarging T2 Lesions were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions</measure>
    <time_frame>LTFU: Baseline up to Week 48</time_frame>
    <description>Enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no New or Enlarging T2 lesions were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITP: Percent Change From Baseline in Brain Volume</measure>
    <time_frame>ITP: Baseline, Week 48 and 96</time_frame>
    <description>Brain volume was measured by using magnetic resonance imaging (MRI) scans. Percent change from baseline in brain volume at Week 48 and 96 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLMP: Percent Change From Baseline in Brain Volume</measure>
    <time_frame>OLMP: Baseline, Week 48 and 96</time_frame>
    <description>Brain volume was measured by using magnetic resonance imaging (MRI) scans. Percent change from baseline in brain volume at Week 48 and 96 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLMP: Number of Relapses</measure>
    <time_frame>Baseline up to Week 96</time_frame>
    <description>Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Relapses</measure>
    <time_frame>Baseline up to Week 48</time_frame>
    <description>Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Relapses</measure>
    <time_frame>Baseline up to Week 48</time_frame>
    <description>Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLMP: Annualized Relapse Rate</measure>
    <time_frame>Baseline up to Week 96</time_frame>
    <description>The annualized relapse rate for each treatment group was the mean of the annualized relapse rates for all the participants in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25. Where, Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLMP: Percentage of Relapse-Free Participants</measure>
    <time_frame>Baseline up to Week 96</time_frame>
    <description>Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Percentage of relapse-free participants were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs</measure>
    <time_frame>ITP: Baseline up to Week 96</time_frame>
    <description>An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. Number of Participants with TEAEs and serious TEAEs were reported.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">617</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cladribine 5.25 mg/kg (ITP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 milligrams per kilograms (mg/kg) during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine 3.5 mg/kg (ITP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (ITP)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine 5.25 mg/kg, Rebif (OLMP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine 3.5 mg/kg, Rebif (OLMP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Rebif (OLMP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine 5.25 mg/kg, Rebif (LTFU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine 3.5 mg/kg, Rebif (LTFU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Rebif (LTFU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Cladribine tablets were administered until CDMS conversion, whichever occur first.</description>
    <arm_group_label>Cladribine 3.5 mg/kg (ITP)</arm_group_label>
    <arm_group_label>Cladribine 3.5 mg/kg, Rebif (LTFU)</arm_group_label>
    <arm_group_label>Cladribine 3.5 mg/kg, Rebif (OLMP)</arm_group_label>
    <arm_group_label>Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</arm_group_label>
    <arm_group_label>Cladribine 5.25 mg/kg (ITP)</arm_group_label>
    <arm_group_label>Cladribine 5.25 mg/kg, Rebif (LTFU)</arm_group_label>
    <arm_group_label>Cladribine 5.25 mg/kg, Rebif (OLMP)</arm_group_label>
    <arm_group_label>Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to cladribine tablets were administered.</description>
    <arm_group_label>Placebo (ITP)</arm_group_label>
    <arm_group_label>Placebo, Rebif (LTFU)</arm_group_label>
    <arm_group_label>Placebo, Rebif (OLMP)</arm_group_label>
    <arm_group_label>Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebif® new formulation (RNF)</intervention_name>
    <description>Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.</description>
    <arm_group_label>Cladribine 3.5 mg/kg (ITP)</arm_group_label>
    <arm_group_label>Cladribine 3.5 mg/kg, Rebif (LTFU)</arm_group_label>
    <arm_group_label>Cladribine 3.5 mg/kg, Rebif (OLMP)</arm_group_label>
    <arm_group_label>Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</arm_group_label>
    <arm_group_label>Cladribine 5.25 mg/kg (ITP)</arm_group_label>
    <arm_group_label>Cladribine 5.25 mg/kg, Rebif (LTFU)</arm_group_label>
    <arm_group_label>Cladribine 5.25 mg/kg, Rebif (OLMP)</arm_group_label>
    <arm_group_label>Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</arm_group_label>
    <arm_group_label>Placebo (ITP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between 18 and 55 years old, inclusive&#xD;
&#xD;
          -  Weighed between 40 to 120 kilogram (kg), inclusive&#xD;
&#xD;
          -  Participant has experienced a single, first clinical event suggestive of MS within 75&#xD;
             days prior to the Screening visit, (clock starts 24 hours after onset). The event must&#xD;
             be a new neurological abnormality present for at least 24 hours, either mono- or&#xD;
             polysymptomatic&#xD;
&#xD;
          -  Participant has at least two clinically silent lesions on the T2-weighted MRI scan, at&#xD;
             screening, with a size of at least 3 millimeter (mm), at least one of which is ovoid&#xD;
             or periventricular or infratentorial on screening MRI&#xD;
&#xD;
          -  Participant has EDSS 0 - 5.0 at Screening&#xD;
&#xD;
          -  Participant has no medical history or evidence of latent tuberculosis infection (LTBI)&#xD;
             or active tubercular disease, as evidenced by the Mantoux tuberculosis (TB) skin test&#xD;
             or a comparable sensitive test according to local regulations/guidelines (if the&#xD;
             Mantoux test is not available), and/or a chest X-ray&#xD;
&#xD;
          -  Participant has normal hematological parameters at Screening, as defined by the&#xD;
             central laboratory that performed all the assessments&#xD;
&#xD;
          -  If female, she must:&#xD;
&#xD;
               -  be neither pregnant nor breast-feeding, nor attempting to conceive and&#xD;
&#xD;
               -  use a highly effective method of contraception throughout the entire duration of&#xD;
                  the study and for 90 days following completion of the last dose of study&#xD;
                  medication. A highly effective method of contraception is defined as those which&#xD;
                  result in a low failure rate (that is less than 1 percent per year) when used&#xD;
                  consistently and correctly such as implants, injectables, combined oral&#xD;
                  contraceptives, some intrauterine devices, sexual abstinence or vasectomized&#xD;
                  partner, or&#xD;
&#xD;
               -  be post-menopausal or surgically sterilized (Note: for Danish sites only,&#xD;
                  participants should use a hormonal contraceptive or intrauterine device for the&#xD;
                  duration of the trial)&#xD;
&#xD;
          -  Male participants must be willing to use contraception to avoid impregnating partners&#xD;
             throughout the study, and for 90 days following the last dose of study medication&#xD;
&#xD;
          -  Be willing and able to comply with study procedures for the duration of the study&#xD;
&#xD;
          -  Participant has to provide written informed consent voluntarily, including, for United&#xD;
             states of America (USA), participant authorization under Health Insurance Portability&#xD;
             and Accountability Act (HIPAA), prior to any study-related procedure that is not part&#xD;
             of normal medical care&#xD;
&#xD;
          -  Participant has refused any treatment already available for clinically isolated&#xD;
             syndrome (CIS) such as interferons or glatiramer acetate, at the time of entry into&#xD;
             the Initial Treatment Period of this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has a diagnosis of MS (per McDonald criteria, 2005)&#xD;
&#xD;
          -  Participant has any other disease that could better explain the participant's signs&#xD;
             and symptoms&#xD;
&#xD;
          -  Participant has complete transverse myelitis or bilateral optic neuritis&#xD;
&#xD;
          -  Participant using or has used any other approved MS disease modifying drug (DMD)&#xD;
&#xD;
          -  Participant has used any investigational drug or undergone an experimental procedure&#xD;
             within 12 weeks prior to Study day 1&#xD;
&#xD;
          -  Participant received oral or systemic corticosteroids or adrenocorticotropic hormone&#xD;
             (ACTH) within 30 days prior to screening MRI. The MRI had to be performed 30 days&#xD;
             after the oral or systemic corticosteroids or ACTH treatment. In case this interfered&#xD;
             with MRI timing the screening period could be extended accordingly.&#xD;
&#xD;
          -  Participant has abnormal total bilirubin, or aspartate aminotransferase (AST) or&#xD;
             alanine aminotransferase (ALT) or alkaline phosphatase greater than 2.5 times the&#xD;
             upper limit of normal&#xD;
&#xD;
          -  Participant suffered from current autoimmune disease other than MS&#xD;
&#xD;
          -  Participant suffered from psychiatric illness (including history of, or concurrent,&#xD;
             severe depressive disorders and/or suicidal ideation) that in the opinion of the&#xD;
             investigator creates undue risk to the participant or could affect compliance with the&#xD;
             study protocol&#xD;
&#xD;
          -  Participant suffered from major medical illness such as cardiac (for example angina,&#xD;
             congestive heart failure or arrhythmia), endocrinologic, hepatic, immunologic,&#xD;
             metabolic, renal, pulmonary, gastrointestinal, dermatologic, or other major disease&#xD;
             that would preclude the administration of oral cladribine&#xD;
&#xD;
          -  Participant has a history of seizures not adequately controlled by medications&#xD;
&#xD;
          -  Participant has a known allergy to cladribine, interferon-beta, the excipient(s) of&#xD;
             the study medications, or to gadolinium- diethylenetriamine penta-acetic acid (DTPA)&#xD;
&#xD;
          -  Participant has any renal condition that would preclude the administration of&#xD;
             gadolinium (for example acute or chronic severe renal insufficiency (glomerular&#xD;
             filtration rate [GFR] less than 30 milliliter per minute per 1.73 square meter&#xD;
             [mL/min/1.73 m^2])&#xD;
&#xD;
          -  Participant has a history of chronic or clinically significant hematological&#xD;
             abnormalities&#xD;
&#xD;
          -  Participant has a history of active or chronic infectious disease or any disease that&#xD;
             compromises immune function (for example human immunodeficiency virus positive [HIV+],&#xD;
             human T-lymphotrophic virus [HTLV-1], Lyme disease, latent tuberculosis infection&#xD;
             [LTBI] or TB, insulin-dependent diabetes).&#xD;
&#xD;
          -  Participant has previously been screened in this study (signed an informed consent)&#xD;
             and then withdrawn&#xD;
&#xD;
          -  Participant has received any immunomodulatory or immunosuppressive therapy) at any&#xD;
             time prior to Study Day 1, including, but not limited to, the following products: any&#xD;
             interferon, glatiramer acetate (Copolymer I), cyclophosphamide, cyclosporine,&#xD;
             methotrexate, linomide, azathioprine, mitoxantrone, teriflunomide, laquinimod,&#xD;
             cladribine, total lymphoid irradiation, anti-lymphocyte monoclonal antibody treatment&#xD;
             (for example natalizumab, alemtuzumab/Campath, anti-cluster of differentiation 4&#xD;
             [CD4]), intravenous immunoglobulin G (IVIG), cytokines or anti-cytokine therapy&#xD;
&#xD;
          -  Participant has received experimental MS treatment&#xD;
&#xD;
          -  Participant has a history of alcohol or drug abuse&#xD;
&#xD;
          -  Participant has intolerance or any contraindication to both paracetamol&#xD;
             (acetaminophen) and ibuprofen&#xD;
&#xD;
          -  Participant has inability to administer subcutaneous injections either by self or by&#xD;
             caregiver&#xD;
&#xD;
          -  Participant has prior or current malignancy (with the exception of in situ basal or&#xD;
             squamous cell skin cancer surgically removed without recurrence for at least five&#xD;
             years)&#xD;
&#xD;
          -  Participant has a positive stool hemoccult test at Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bettina Stubinski, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono S.A., Geneva</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hope Research Institute Medical Plaza LLC Desert Hills</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple Sclerosis Center Drive, Neurology Suite 701</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado at Denver Health Sciences</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Collins Neurology</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center of Brevard MIMA Centry Research Associates</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bruce Hughes West Building</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Neurology Associates</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dennis Dietrich</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Medicine and Dentistry of New Jersey School of Neurology</name>
      <address>
        <city>Stratford</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research LLC 3</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Specialists of Long Island</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple Sclerosis Center of Northeastern NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive MS Care Clinic at South Shore Multiple Sclerosis</name>
      <address>
        <city>Patchogue</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meritcare Neuroscience Center Neurology</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology and Sleep Medicine</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center Cherry Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology &amp; Neurological Association of Tacoma</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Rodriguez Alfici</name>
      <address>
        <city>Godoy Cruz</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Rosarina de Neurorehabilitacion</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis St Jan</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liege - Domaine Universitaire du Sart Tilman,</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center University of Sarajevo</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy- Sofia (MMA)</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBAL Rousse AD 1st</name>
      <address>
        <city>Rousse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinic Hospital</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Hospital</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second MHAT</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokuda Hospital</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital St Naum</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre Centromed 2000</name>
      <address>
        <city>Veliko Tarnovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa General Hospital</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Varazdin</name>
      <address>
        <city>Varazdin</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zagreb</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological dept of Faculty</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice s poliklinikou Ostrava</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Motol</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Vseobecne</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Teplice</name>
      <address>
        <city>Teplice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUS Hyvinkaa Central Hospital</name>
      <address>
        <city>Hyvinkaa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OYKS Neurologian Klinikka</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologian Klinikka Seinajoen Keskussairaala</name>
      <address>
        <city>Seinajoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turun Yliopistollinen Keskussairaala Rakennus 3 1</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Memorial Hospital</name>
      <address>
        <city>Reims Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Tatishvili Medical Center</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Health</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Khechinashvili Tbilisi State Medical University</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum und Medizinische Fakultaet Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps-Universitaet Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M S Ramaiah Medical College Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.John's Medical College and Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences and Research</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kovai Medical Centre and Hospital</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanjay Gandhi Post Graduate Institute of Medical Sciences</name>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mallikatta Neuro and Research Centre</name>
      <address>
        <city>Mangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale Torrette</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università de Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Binaghi Centro Sclerosi Multipla</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Garibaldi</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Neuroscienze</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università G. D'Annunzio</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Antonio Abate</name>
      <address>
        <city>Gallarate</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale e casa di riposo P. Richiedei</name>
      <address>
        <city>Gussago</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze Neurologiche</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedaliera San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Villa Sofia Hospital Azienda Ospedaliera Villa Sofia P.zza Salerno e Resuttana 1</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Neurologico C. Mondino</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Roma La Sapienza</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center, Department of Neurology,</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, 50 Ilwon-dong, Gangnam-gu</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Asan Medical Center, 388-1 Pungnap 2-dong, Songpa-gu</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital, Department of Neurology</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Medical Center, Department of Neurology, Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American University of Beirut</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Neurology &quot;Klinicki Centar&quot;</name>
      <address>
        <city>Skopje</city>
        <country>North Macedonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helse Bergen HF Kvinneklinikken Haukeland Universitetssykehus Jonas</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionsykehuset I Trondheim, Nevrologisk avd.</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10 Wojskowy Szpital Kliniczny</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. M. Kopernika</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zespol Opieki Zdrowotnej</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Academy of Lodz</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panstwowy Szpital Kliniczny</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny Oddział Neurologii z Pododdziałem Udarowym</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Academy</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Academy II</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Academy</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fernando da Fonseca</name>
      <address>
        <city>Amadora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitais da Universidade de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Coimbra</name>
      <address>
        <city>S. Martinho Do Bispo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Dr. Carol Davilla&quot; Military Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical SANA</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean Mures</name>
      <address>
        <city>Targu-Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Hospital Timisoara</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution &quot;City Clinical Hospital #3&quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Sverdlovsk Regional Clinical Hospital #1&quot;</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Kaluga Regional Hospital&quot;</name>
      <address>
        <city>Kaluga</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Institution &quot;Republican Rehabilitation Clinic of Tatarstan Ministry of Health&quot;</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Kemerovo Regional Clinical Hospital&quot;</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Institution &quot; Jursk Regional Clinical Hospital&quot;</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Healthcare Institution City Clinical Hospital #11</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-State Healthcare Institution &quot;Central Clinical Hospital #2 named after N.A. Semasko of Russian Railways&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institute of Higher Professional Education &quot;I.M. Sechenov Moscow Medical Academy of Roszdrav&quot; Russia based on A. Ya. Kozhevnikov Nervous Disease Clinic</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Treatment Prophylactic Institution &quot;City Hospital #33&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot; Siberian Reginal Medical Center of Roszdarv&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State institution Science Research Institute Clinical and Experimental Lymphology of Russian Academy of Medical Sciences</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institute of Higher Professional Education &quot;Rostov State Medical University of Roszdrav&quot;</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Rostov Region Clinical Hospital&quot;</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Military Medical Academy named after S. M. Korov of Dept of Defense of Russian Federation based on Clinic of Neurology of State Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Samara State Medical University of Roszdrav&quot; on State Healthcare Institution &quot;Samara Regional Clinical Hospital named after M. I. Kalinin&quot;</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Saratov State Medical University of Roszdrav&quot; based on Clincial Hosptial #3 of Saratov State Medical University</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State Healthcare Institution &quot;State Smolensk Region Clinical Hospital&quot;</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Human Brain of Russian Academy of Science Dept. of Multiple Sclerosis</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinic and Hospital, Neurology</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Healthcare Institution &quot;Multifield City Hospital #2&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Siberian State Medical University of Roszdrav&quot;</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Closed joint-stock society Medical sanitary unit &quot;Nephtaynik&quot; based the hospital</name>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vladimir Regional State Healthcare Institution &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Vladimir</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution &quot;Yaroslavi Clinical Hospital #8&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Prevention and Treatment of Cerebro-Vascular Diseases</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Niš</name>
      <address>
        <city>Niš</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Neuroscience Institute (TTSH Campus)</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia Cordoba</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Senora de la Candelaria</name>
      <address>
        <city>Sta. Cruz de Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenskasjukhuset</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umea University Hospital</name>
      <address>
        <city>Umea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation- Linkou Branch No5</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayis Universitesi</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Established &quot;Institute of Neurology, Psychiatry and Narcology of the AMS of Ukraine&quot;, Depart of Neurinfections and Multiple Sclorosis</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institue for Clinical Radiology of the State Establishment &quot;Research Centre for Radiation Medicine of the AMS of Ukraino&quot; Depart of Radiation Psychoneurology</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnylsia Regional Psychoneurological Hosptial Named After O. I Yushchenko, Neurological Depart, Vinnytsia National Medical University Named After M. I. Pirogov, Chair of Neurology</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rashid Hospital</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lebanon</country>
    <country>North Macedonia</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Arab Emirates</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Saudi Arabia</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=28821</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 30, 2008</study_first_submitted>
  <study_first_submitted_qc>July 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2008</study_first_posted>
  <results_first_submitted>June 11, 2013</results_first_submitted>
  <results_first_submitted_qc>August 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2013</results_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinically Isolated Syndrome (CIS)</keyword>
  <keyword>Early MS</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 617 participants were randomized for initial treatment period (ITP) and 616 participants received study drug.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cladribine 5.25 mg/kg (ITP)</title>
          <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
        </group>
        <group group_id="P2">
          <title>Cladribine 3.5 mg/kg (ITP)</title>
          <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
        </group>
        <group group_id="P3">
          <title>Placebo (ITP)</title>
          <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
        </group>
        <group group_id="P4">
          <title>Cladribine 5.25 mg/kg, Rebif (OLMP)</title>
          <description>Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
        </group>
        <group group_id="P5">
          <title>Cladribine 3.5 mg/kg, Rebif (OLMP)</title>
          <description>Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
        </group>
        <group group_id="P6">
          <title>Placebo, Rebif (OLMP)</title>
          <description>Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
        </group>
        <group group_id="P7">
          <title>Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
          <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
        </group>
        <group group_id="P8">
          <title>Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
          <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
        </group>
        <group group_id="P9">
          <title>Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
          <description>Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
        </group>
        <group group_id="P10">
          <title>Cladribine 5.25 mg/kg, Rebif (LTFU)</title>
          <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
        </group>
        <group group_id="P11">
          <title>Cladribine 3.5 mg/kg, Rebif (LTFU)</title>
          <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
        </group>
        <group group_id="P12">
          <title>Placebo, Rebif (LTFU)</title>
          <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>ITP- Treatment Disposition</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="206"/>
                <participants group_id="P3" count="206"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="206"/>
                <participants group_id="P3" count="206"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="131"/>
                <participants group_id="P3" count="104"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="102"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Converted to CDMS</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>OLMP (Up to 96 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="60"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="53"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="44"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>LTFU (Cladribine Treatment) (48 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="17"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="17"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="16"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>LTFU (No Cladribine) (48 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="34"/>
                <participants group_id="P11" count="36"/>
                <participants group_id="P12" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="34"/>
                <participants group_id="P11" count="36"/>
                <participants group_id="P12" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="34"/>
                <participants group_id="P11" count="36"/>
                <participants group_id="P12" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent-to-treat (ITT) population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).</population>
      <group_list>
        <group group_id="B1">
          <title>Cladribine 5.25 mg/kg</title>
          <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first. Participants who converted to CDMS during ITP entered OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Participants who did not convert to CDMS during ITP, entered in LTFU period. Participants who converted to McDonald MS during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period.</description>
        </group>
        <group group_id="B2">
          <title>Cladribine 3.5 mg/kg</title>
          <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first. Participants who converted to CDMS during ITP entered OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Participants who did not convert to CDMS during ITP, entered in LTFU period. Participants who converted to McDonald MS during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any study treatment during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first. Participants who converted to CDMS during ITP entered OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Participants who did not convert to CDMS during ITP, entered in LTFU period. Participants who converted to McDonald MS during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any study treatment during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="204"/>
            <count group_id="B2" value="206"/>
            <count group_id="B3" value="206"/>
            <count group_id="B4" value="616"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.9" spread="8.8"/>
                    <measurement group_id="B2" value="31.7" spread="9.2"/>
                    <measurement group_id="B3" value="32.2" spread="8.2"/>
                    <measurement group_id="B4" value="31.9" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Greater than or equal to 30 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="334"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Less than 30 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="138"/>
                    <measurement group_id="B4" value="400"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expanded disability status scale (EDSS) score</title>
          <description>Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" spread="0.9"/>
                    <measurement group_id="B2" value="1.6" spread="0.9"/>
                    <measurement group_id="B3" value="1.7" spread="0.9"/>
                    <measurement group_id="B4" value="1.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Time Constant 1 (T1) Gadolinium Enhanced (GD+) lesions</title>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" spread="5.8"/>
                    <measurement group_id="B2" value="1.5" spread="4.5"/>
                    <measurement group_id="B3" value="0.9" spread="2.5"/>
                    <measurement group_id="B4" value="1.4" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of T2 Lesions</title>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.7" spread="29.6"/>
                    <measurement group_id="B2" value="26.8" spread="28.3"/>
                    <measurement group_id="B3" value="26.3" spread="27.4"/>
                    <measurement group_id="B4" value="27.6" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from First Demyelinating Event to Randomization</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.35" spread="17.61"/>
                    <measurement group_id="B2" value="78.67" spread="15.97"/>
                    <measurement group_id="B3" value="79.40" spread="17.94"/>
                    <measurement group_id="B4" value="79.14" spread="17.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Monofocal/Multifocal Classification (By Adjudication Committee)</title>
          <description>Monofocal- Neurological signs and symptoms can be explained by only 1 single location; Multifocal- Neurological signs and symptoms can not be explained by only 1 single location.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Monofocal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multifocal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants Using Steroid Treatment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Participants with Time Constant 1 (T1) Gd-enhanced Lesions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS</title>
        <description>CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to Multiple Sclerosis [MS]) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (&gt;=) 1 point if baseline EDSS was between &gt;= 1.0 and less than or equal to (=&lt;) 4.5; or &gt;= 1.5 points if baseline EDSS was 0, or &gt;= 0.5 if baseline EDSS &gt;= 5.0 over a period of at least 3 months. Kaplan-Meier estimates were provided for of the cumulative (cum.) percentage (%) of participants with CDMS over time. The probability of patients remaining event-free over time (from randomization) in each of the three treatment groups was displayed in the form of survival curves estimated using the non-parametric Kaplan-Meier method.</description>
        <time_frame>ITP: Baseline up to Week 96</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS</title>
          <description>CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to Multiple Sclerosis [MS]) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (&gt;=) 1 point if baseline EDSS was between &gt;= 1.0 and less than or equal to (=&lt;) 4.5; or &gt;= 1.5 points if baseline EDSS was 0, or &gt;= 0.5 if baseline EDSS &gt;= 5.0 over a period of at least 3 months. Kaplan-Meier estimates were provided for of the cumulative (cum.) percentage (%) of participants with CDMS over time. The probability of patients remaining event-free over time (from randomization) in each of the three treatment groups was displayed in the form of survival curves estimated using the non-parametric Kaplan-Meier method.</description>
          <population>The intent-to-treat (ITT) population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).</population>
          <units>Cum. % of participants with CDMS</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8"/>
                    <measurement group_id="O2" value="14.0"/>
                    <measurement group_id="O3" value="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The treatment effect was also assessed by hazard ratios using the Cox's proportional hazards model.</p_value_desc>
            <method>two-sided Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.381</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.248</ci_lower_limit>
            <ci_upper_limit>0.584</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The treatment effect was also assessed by hazard ratios using the Cox's proportional hazards model.</p_value_desc>
            <method>two-sided Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.327</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.210</ci_lower_limit>
            <ci_upper_limit>0.509</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ITP: Time to Develop Multiple Sclerosis (MS) Conversion According to the Revised McDonald Criteria (2005) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With McDonald MS</title>
        <description>The McDonald criteria use dissemination in time and space established by magnetic resonance imaging (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium enhanced (Gd+) lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions. Kaplan-Meier estimates were provided for the cum. percentage (%) of participants with McDonald MS over time.</description>
        <time_frame>ITP: Baseline up to Week 96</time_frame>
        <population>The ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Time to Develop Multiple Sclerosis (MS) Conversion According to the Revised McDonald Criteria (2005) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With McDonald MS</title>
          <description>The McDonald criteria use dissemination in time and space established by magnetic resonance imaging (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium enhanced (Gd+) lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions. Kaplan-Meier estimates were provided for the cum. percentage (%) of participants with McDonald MS over time.</description>
          <population>The ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).</population>
          <units>Cum. % of participants with McDonald MS</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.36"/>
                    <measurement group_id="O2" value="56.05"/>
                    <measurement group_id="O3" value="87.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The treatment effect was also assessed by hazard ratios using the Cox's proportional hazards model.</p_value_desc>
            <method>two-sided Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.425</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.331</ci_lower_limit>
            <ci_upper_limit>0.547</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The treatment effect was also assessed by hazard ratios using the Cox's proportional hazards model.</p_value_desc>
            <method>two-sided Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.497</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.390</ci_lower_limit>
            <ci_upper_limit>0.633</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ITP: Number of Combined Unique Active (CUA) Lesions, New or Enlarging Time Constant 2 (T2) Lesions, and New or Persisting Time Constant 1 (T1) Gadolinium Enhanced (Gd+) Lesions Per Participant Per Scan</title>
        <description>Number of CUA lesions, new or enlarging T2 lesions, and new or persisting T1 Gd+ lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>ITP: Baseline up to Week 96</time_frame>
        <population>The ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo). Here &quot;Number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Number of Combined Unique Active (CUA) Lesions, New or Enlarging Time Constant 2 (T2) Lesions, and New or Persisting Time Constant 1 (T1) Gadolinium Enhanced (Gd+) Lesions Per Participant Per Scan</title>
          <description>Number of CUA lesions, new or enlarging T2 lesions, and new or persisting T1 Gd+ lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>The ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo). Here &quot;Number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CUA lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="5.79"/>
                    <measurement group_id="O2" value="0.65" spread="1.80"/>
                    <measurement group_id="O3" value="2.13" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or persisting T1 Gd+ lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="5.33"/>
                    <measurement group_id="O2" value="0.29" spread="0.97"/>
                    <measurement group_id="O3" value="0.97" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or enlarging T2 lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="1.90"/>
                    <measurement group_id="O2" value="0.40" spread="1.12"/>
                    <measurement group_id="O3" value="1.17" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>CUA lesions</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.667</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.971</ci_lower_limit>
            <ci_upper_limit>-0.500</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>CUA lesions</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.625</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.857</ci_lower_limit>
            <ci_upper_limit>-0.429</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>T1 Gd-Enhancing Lesions</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.286</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.333</ci_lower_limit>
            <ci_upper_limit>-0.167</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>T1 Gd-Enhancing Lesions</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.286</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.375</ci_lower_limit>
            <ci_upper_limit>-0.167</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>T2 Lesions</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.333</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.500</ci_lower_limit>
            <ci_upper_limit>-0.167</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>T2 Lesions</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.286</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.429</ci_lower_limit>
            <ci_upper_limit>-0.143</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLMP: Time to 3 Month Confirmed Expanded Disability Status Scale (EDSS) Progression From Randomization Represented by Kaplan-Meier Estimates of Probability of Disability Progression</title>
        <description>EDSS progression is based on a standardized neurological exam and focuses on symptoms that commonly occur in Multiple Sclerosis (MS). Overall scores ranges from 0.0 (normal) to 10.0 (death due to MS). A sustained progression on EDSS score was defined as an EDSS progression confirmed into two consecutive assessment. Probability of disability progression at different time points was estimated using Kaplan-Meier method on the time to disability progression defined as the time from randomization to first EDSS increase.</description>
        <time_frame>OLMP: Day 1, 90, 180, 270, 360, 450, 540, 630, 720 and 810</time_frame>
        <population>OLMP Analysis Set included all participants who received at least 1 dose of study medication, converted to CDMS in the ITP period, entered the OLMP and received at least 1 dose of OLMP study drug (Rebif). Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (OLMP)</title>
            <description>Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
        </group_list>
        <measure>
          <title>OLMP: Time to 3 Month Confirmed Expanded Disability Status Scale (EDSS) Progression From Randomization Represented by Kaplan-Meier Estimates of Probability of Disability Progression</title>
          <description>EDSS progression is based on a standardized neurological exam and focuses on symptoms that commonly occur in Multiple Sclerosis (MS). Overall scores ranges from 0.0 (normal) to 10.0 (death due to MS). A sustained progression on EDSS score was defined as an EDSS progression confirmed into two consecutive assessment. Probability of disability progression at different time points was estimated using Kaplan-Meier method on the time to disability progression defined as the time from randomization to first EDSS increase.</description>
          <population>OLMP Analysis Set included all participants who received at least 1 dose of study medication, converted to CDMS in the ITP period, entered the OLMP and received at least 1 dose of OLMP study drug (Rebif). Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
          <units>Probability of Disability Progression</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O2" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O3" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O2" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O3" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0417" lower_limit="-0.0383" upper_limit="0.1216"/>
                    <measurement group_id="O2" value="0.0417" lower_limit="-0.0383" upper_limit="0.1216"/>
                    <measurement group_id="O3" value="0.0527" lower_limit="-0.0054" upper_limit="0.1108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0417" lower_limit="-0.0383" upper_limit="0.1216"/>
                    <measurement group_id="O2" value="0.0417" lower_limit="-0.0383" upper_limit="0.1216"/>
                    <measurement group_id="O3" value="0.0527" lower_limit="-0.0054" upper_limit="0.1108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 360</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0417" lower_limit="-0.0383" upper_limit="0.1216"/>
                    <measurement group_id="O2" value="0.0417" lower_limit="-0.0383" upper_limit="0.1216"/>
                    <measurement group_id="O3" value="0.0527" lower_limit="-0.0054" upper_limit="0.1108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 450</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0417" lower_limit="-0.0383" upper_limit="0.1216"/>
                    <measurement group_id="O2" value="0.0417" lower_limit="-0.0383" upper_limit="0.1216"/>
                    <measurement group_id="O3" value="0.0764" lower_limit="0.0035" upper_limit="0.1492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 540</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0417" lower_limit="-0.0383" upper_limit="0.1216"/>
                    <measurement group_id="O2" value="0.0417" lower_limit="-0.0383" upper_limit="0.1216"/>
                    <measurement group_id="O3" value="0.1094" lower_limit="0.0147" upper_limit="0.2041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 630</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0417" lower_limit="-0.0383" upper_limit="0.1216"/>
                    <measurement group_id="O2" value="0.0417" lower_limit="-0.0383" upper_limit="0.1216"/>
                    <measurement group_id="O3" value="0.1094" lower_limit="0.0147" upper_limit="0.2041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 720</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0417" lower_limit="-0.0383" upper_limit="0.1216"/>
                    <measurement group_id="O2" value="0.0417" lower_limit="-0.0383" upper_limit="0.1216"/>
                    <measurement group_id="O3" value="0.1094" lower_limit="0.0147" upper_limit="0.2041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 810</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Multiple Sclerosis (MS) According to the 2005 McDonald Criteria</title>
        <description>The McDonald criteria use dissemination in time and space established by magnetic resonance imaging (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium enhanced (Gd+) lesion found on a repeat MRI.</description>
        <time_frame>Time from Randomization up to 1217 days</time_frame>
        <population>LTFU analysis set (No Treatment at LTFU Entry) consists of all participants who completed the 96-week ITP and entered the LTFU for safety follow-up and did not receive study treatment upon entry to the LTFU. Here &quot;Number of Participants analyzed&quot; signifies those participants who have been converted to CDMS.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Multiple Sclerosis (MS) According to the 2005 McDonald Criteria</title>
          <description>The McDonald criteria use dissemination in time and space established by magnetic resonance imaging (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium enhanced (Gd+) lesion found on a repeat MRI.</description>
          <population>LTFU analysis set (No Treatment at LTFU Entry) consists of all participants who completed the 96-week ITP and entered the LTFU for safety follow-up and did not receive study treatment upon entry to the LTFU. Here &quot;Number of Participants analyzed&quot; signifies those participants who have been converted to CDMS.</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria</title>
        <description>CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (&gt;=) 1 point if baseline EDSS was between &gt;= 1.0 and less than or equal to (=&lt;) 4.5; or &gt;= 1.5 points if baseline EDSS was 0, or &gt;= 0.5 if baseline EDSS &gt;= 5.0 over a period of at least 3 months.</description>
        <time_frame>Time from Randomization up to 1217 days</time_frame>
        <population>LTFU analysis set (No Treatment at LTFU Entry) was used. Here &quot;Number of Participants Analyzed&quot; signifies those participants who have been converted to CDMS.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria</title>
          <description>CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (&gt;=) 1 point if baseline EDSS was between &gt;= 1.0 and less than or equal to (=&lt;) 4.5; or &gt;= 1.5 points if baseline EDSS was 0, or &gt;= 0.5 if baseline EDSS &gt;= 5.0 over a period of at least 3 months.</description>
          <population>LTFU analysis set (No Treatment at LTFU Entry) was used. Here &quot;Number of Participants Analyzed&quot; signifies those participants who have been converted to CDMS.</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria</title>
        <description>CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (&gt;=) 1 point if baseline EDSS was between &gt;= 1.0 and less than or equal to (=&lt;) 4.5; or &gt;= 1.5 points if baseline EDSS was 0, or &gt;= 0.5 if baseline EDSS &gt;= 5.0 over a period of at least 3 months.</description>
        <time_frame>Time from Randomization up to 1217 days</time_frame>
        <population>LTFU analysis set (Treated at LTFU Entry) analysis set consisted of all participants who converted to McDonald MS (2005) during the ITP, completed ITP 96-weeks and entered the LTFU. Here &quot;Number of Participants analyzed&quot; signifies those participants who have been converted to CDMS.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria</title>
          <description>CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (&gt;=) 1 point if baseline EDSS was between &gt;= 1.0 and less than or equal to (=&lt;) 4.5; or &gt;= 1.5 points if baseline EDSS was 0, or &gt;= 0.5 if baseline EDSS &gt;= 5.0 over a period of at least 3 months.</description>
          <population>LTFU analysis set (Treated at LTFU Entry) analysis set consisted of all participants who converted to McDonald MS (2005) during the ITP, completed ITP 96-weeks and entered the LTFU. Here &quot;Number of Participants analyzed&quot; signifies those participants who have been converted to CDMS.</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ITP: Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) as Per Poser Criteria</title>
        <description>Clinically definite multiple sclerosis (CDMS) according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (&gt;=) 1 point if baseline EDSS was between &gt;= 1.0 and less than or equal to (=&lt;) 4.5; or &gt;= 1.5 points if baseline EDSS was 0, or &gt;= 0.5 if baseline EDSS &gt;= 5.0 over a period of at least 3 months. The percentage of participants who converted to CDMS are reported here.</description>
        <time_frame>ITP: Baseline up to week 96</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) as Per Poser Criteria</title>
          <description>Clinically definite multiple sclerosis (CDMS) according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (&gt;=) 1 point if baseline EDSS was between &gt;= 1.0 and less than or equal to (=&lt;) 4.5; or &gt;= 1.5 points if baseline EDSS was 0, or &gt;= 0.5 if baseline EDSS &gt;= 5.0 over a period of at least 3 months. The percentage of participants who converted to CDMS are reported here.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ITP: Percentage of Participants Converting to McDonald Multiple Sclerosis (MS) (2005)</title>
        <description>Percentage of participants converting to mcDonald multiple sclerosis (2005) were reported.</description>
        <time_frame>ITP: Baseline up to week 96</time_frame>
        <population>Intent-to-Treat analysis set included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Percentage of Participants Converting to McDonald Multiple Sclerosis (MS) (2005)</title>
          <description>Percentage of participants converting to mcDonald multiple sclerosis (2005) were reported.</description>
          <population>Intent-to-Treat analysis set included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7"/>
                    <measurement group_id="O2" value="71.6"/>
                    <measurement group_id="O3" value="91.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ITP: Number of New or Persisting Gd-enhanced Lesions</title>
        <description>Number of new or persisting Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo). Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Number of New or Persisting Gd-enhanced Lesions</title>
          <description>Number of new or persisting Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>The intent-to-treat (ITT) population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo). Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="189"/>
                    <count group_id="O3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="5.60"/>
                    <measurement group_id="O2" value="0.37" spread="1.52"/>
                    <measurement group_id="O3" value="1.00" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="171"/>
                    <count group_id="O2" value="186"/>
                    <count group_id="O3" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.20"/>
                    <measurement group_id="O2" value="0.13" spread="0.51"/>
                    <measurement group_id="O3" value="0.92" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="115"/>
                    <count group_id="O3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.38"/>
                    <measurement group_id="O2" value="0.14" spread="0.44"/>
                    <measurement group_id="O3" value="0.74" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="163"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="143"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.13"/>
                    <measurement group_id="O2" value="0.27" spread="0.92"/>
                    <measurement group_id="O3" value="0.87" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="148"/>
                    <count group_id="O3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.84"/>
                    <measurement group_id="O2" value="0.22" spread="0.94"/>
                    <measurement group_id="O3" value="0.74" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="146"/>
                    <count group_id="O3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.53"/>
                    <measurement group_id="O2" value="0.16" spread="0.81"/>
                    <measurement group_id="O3" value="0.90" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="126"/>
                    <count group_id="O3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.13"/>
                    <measurement group_id="O2" value="0.32" spread="2.62"/>
                    <measurement group_id="O3" value="0.60" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.43"/>
                    <measurement group_id="O2" value="0.18" spread="0.84"/>
                    <measurement group_id="O3" value="0.64" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLMP: Number of New or Persisting Gd-enhanced Lesions</title>
        <description>Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>OLMP: Baseline, Week 24, 48, 72 and 96</time_frame>
        <population>OLMP Analysis Set included all participants who received at least 1 dose of study drug, converted to CDMS in ITP period, entered OLMP and received at least 1 dose of OLMP study drug. Here &quot;Number of participants analyzed&quot; = participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; = who were evaluable at specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (OLMP)</title>
            <description>Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
        </group_list>
        <measure>
          <title>OLMP: Number of New or Persisting Gd-enhanced Lesions</title>
          <description>Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>OLMP Analysis Set included all participants who received at least 1 dose of study drug, converted to CDMS in ITP period, entered OLMP and received at least 1 dose of OLMP study drug. Here &quot;Number of participants analyzed&quot; = participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; = who were evaluable at specified time point.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="5.52"/>
                    <measurement group_id="O2" value="0.88" spread="1.80"/>
                    <measurement group_id="O3" value="1.27" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.48"/>
                    <measurement group_id="O2" value="0.05" spread="0.21"/>
                    <measurement group_id="O3" value="0.11" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.24"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.20" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="3.28"/>
                    <measurement group_id="O2" value="0.13" spread="0.35"/>
                    <measurement group_id="O3" value="0.33" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="2.69"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.07" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions</title>
        <description>Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>LTFU: Baseline, Week 13, 24 and 36</time_frame>
        <population>LTFU analysis set (Treated at LTFU Entry) analysis set consisted of all participants who converted to McDonald MS (2005) during the ITP, completed ITP 96-weeks and entered the LTFU. Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions</title>
          <description>Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>LTFU analysis set (Treated at LTFU Entry) analysis set consisted of all participants who converted to McDonald MS (2005) during the ITP, completed ITP 96-weeks and entered the LTFU. Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.71" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.13" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.18" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions</title>
        <description>Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>LTFU: Baseline, Week 13, 24, 36 and 48</time_frame>
        <population>LTFU analysis set (No Treatment at LTFU Entry) was used. Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions</title>
          <description>Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>LTFU analysis set (No Treatment at LTFU Entry) was used. Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.06" spread="0.23"/>
                    <measurement group_id="O3" value="0.14" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.07" spread="0.23"/>
                    <measurement group_id="O3" value="0.09" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.20" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.17" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ITP: Number of New or Enlarging T2 Lesions</title>
        <description>Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo). Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Number of New or Enlarging T2 Lesions</title>
          <description>Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>The intent-to-treat (ITT) population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo). Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="189"/>
                    <count group_id="O3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="3.52"/>
                    <measurement group_id="O2" value="1.25" spread="3.33"/>
                    <measurement group_id="O3" value="1.43" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="171"/>
                    <count group_id="O2" value="186"/>
                    <count group_id="O3" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.95"/>
                    <measurement group_id="O2" value="0.20" spread="0.66"/>
                    <measurement group_id="O3" value="1.01" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="115"/>
                    <count group_id="O3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.40"/>
                    <measurement group_id="O2" value="0.12" spread="0.42"/>
                    <measurement group_id="O3" value="1.14" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="143"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.50"/>
                    <measurement group_id="O2" value="0.32" spread="2.52"/>
                    <measurement group_id="O3" value="1.04" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="148"/>
                    <count group_id="O3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.63"/>
                    <measurement group_id="O2" value="0.25" spread="1.09"/>
                    <measurement group_id="O3" value="0.71" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="148"/>
                    <count group_id="O3" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.22"/>
                    <measurement group_id="O2" value="0.10" spread="0.34"/>
                    <measurement group_id="O3" value="0.83" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.46"/>
                    <measurement group_id="O2" value="0.28" spread="2.03"/>
                    <measurement group_id="O3" value="0.61" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.25"/>
                    <measurement group_id="O2" value="0.10" spread="0.59"/>
                    <measurement group_id="O3" value="0.38" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLMP: Number of New or Enlarging T2 Lesions</title>
        <description>Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>OLMP: Baseline, Week 24, 48, 72 and 96</time_frame>
        <population>OLMP Analysis Set included all participants who received at least 1 dose of study drug, converted to CDMS in ITP period, entered OLMP and received at least 1 dose of OLMP study drug. Here &quot;Number of participants analyzed&quot; = participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; = who were evaluable at specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (OLMP)</title>
            <description>Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
        </group_list>
        <measure>
          <title>OLMP: Number of New or Enlarging T2 Lesions</title>
          <description>Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>OLMP Analysis Set included all participants who received at least 1 dose of study drug, converted to CDMS in ITP period, entered OLMP and received at least 1 dose of OLMP study drug. Here &quot;Number of participants analyzed&quot; = participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; = who were evaluable at specified time point.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.75"/>
                    <measurement group_id="O2" value="1.54" spread="6.72"/>
                    <measurement group_id="O3" value="2.13" spread="7.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.69"/>
                    <measurement group_id="O2" value="0.43" spread="1.35"/>
                    <measurement group_id="O3" value="0.68" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.65"/>
                    <measurement group_id="O2" value="0.38" spread="1.09"/>
                    <measurement group_id="O3" value="0.41" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="1.85"/>
                    <measurement group_id="O2" value="0.25" spread="0.46"/>
                    <measurement group_id="O3" value="0.97" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="3.52"/>
                    <measurement group_id="O2" value="0.67" spread="1.15"/>
                    <measurement group_id="O3" value="0.47" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Enlarging T2 Lesions</title>
        <description>Number of new or enlarging T2 Lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>LTFU: Baseline, Week 13, 24 and 36</time_frame>
        <population>LTFU analysis set (Treated at LTFU Entry) analysis set consisted of all participants who converted to McDonald MS (2005) during the ITP, completed ITP 96-weeks and entered the LTFU. Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Enlarging T2 Lesions</title>
          <description>Number of new or enlarging T2 Lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>LTFU analysis set (Treated at LTFU Entry) analysis set consisted of all participants who converted to McDonald MS (2005) during the ITP, completed ITP 96-weeks and entered the LTFU. Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.71" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.25" spread="0.46"/>
                    <measurement group_id="O3" value="2.06" spread="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.10" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Enlarging T2 Lesions</title>
        <description>Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>LTFU: Baseline, Week 13, 24, 36 and 48</time_frame>
        <population>LTFU analysis set (No Treatment at LTFU Entry) was used. Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Enlarging T2 Lesions</title>
          <description>Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>LTFU analysis set (No Treatment at LTFU Entry) was used. Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.03" spread="0.17"/>
                    <measurement group_id="O3" value="0.07" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.04" spread="0.21"/>
                    <measurement group_id="O3" value="0.18" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.13" spread="0.35"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.33" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ITP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions</title>
        <description>Number of CUA lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of ITP study medication. Here &quot;Number of participants analyzed&quot; signifies those who were evaluable for this outcome measure and &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions</title>
          <description>Number of CUA lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of ITP study medication. Here &quot;Number of participants analyzed&quot; signifies those who were evaluable for this outcome measure and &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="189"/>
                    <count group_id="O2" value="189"/>
                    <count group_id="O3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="6.87"/>
                    <measurement group_id="O2" value="1.56" spread="4.04"/>
                    <measurement group_id="O3" value="2.41" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="171"/>
                    <count group_id="O2" value="186"/>
                    <count group_id="O3" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="1.03"/>
                    <measurement group_id="O2" value="0.29" spread="0.89"/>
                    <measurement group_id="O3" value="1.91" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="115"/>
                    <count group_id="O3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.71"/>
                    <measurement group_id="O2" value="0.25" spread="0.70"/>
                    <measurement group_id="O3" value="1.84" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="143"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.59"/>
                    <measurement group_id="O2" value="0.56" spread="3.05"/>
                    <measurement group_id="O3" value="1.89" spread="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="149"/>
                    <count group_id="O3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="1.40"/>
                    <measurement group_id="O2" value="0.42" spread="1.87"/>
                    <measurement group_id="O3" value="1.44" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="148"/>
                    <count group_id="O3" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.72"/>
                    <measurement group_id="O2" value="0.22" spread="1.03"/>
                    <measurement group_id="O3" value="1.66" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.51"/>
                    <measurement group_id="O2" value="0.55" spread="4.52"/>
                    <measurement group_id="O3" value="1.14" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.60"/>
                    <measurement group_id="O2" value="0.23" spread="1.39"/>
                    <measurement group_id="O3" value="0.99" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLMP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions</title>
        <description>Number of combined unique active (CUA) lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>OLMP: Baseline, Week 24, 48, 72 and 96</time_frame>
        <population>OLMP Analysis Set included all participants who received at least 1 dose of study drug, converted to CDMS in ITP period, entered OLMP and received at least 1 dose of OLMP study drug. Here &quot;Number of participants analyzed&quot; = participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; = who were evaluable at specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (OLMP)</title>
            <description>Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
        </group_list>
        <measure>
          <title>OLMP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions</title>
          <description>Number of combined unique active (CUA) lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>OLMP Analysis Set included all participants who received at least 1 dose of study drug, converted to CDMS in ITP period, entered OLMP and received at least 1 dose of OLMP study drug. Here &quot;Number of participants analyzed&quot; = participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; = who were evaluable at specified time point.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="1.17"/>
                    <measurement group_id="O2" value="2.17" spread="7.72"/>
                    <measurement group_id="O3" value="3.23" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="1.02"/>
                    <measurement group_id="O2" value="0.48" spread="1.40"/>
                    <measurement group_id="O3" value="0.79" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.81"/>
                    <measurement group_id="O2" value="0.38" spread="1.09"/>
                    <measurement group_id="O3" value="0.61" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="5.01"/>
                    <measurement group_id="O2" value="0.38" spread="0.74"/>
                    <measurement group_id="O3" value="1.30" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="6.03"/>
                    <measurement group_id="O2" value="0.67" spread="1.15"/>
                    <measurement group_id="O3" value="0.53" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions</title>
        <description>Number of CUA MRI lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>LTFU: Baseline, Week 13, 24 and 36</time_frame>
        <population>LTFU analysis set (Treated at LTFU Entry) analysis set consisted of all participants who converted to McDonald MS (2005) during the ITP, completed ITP 96-weeks and entered the LTFU. Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions</title>
          <description>Number of CUA MRI lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>LTFU analysis set (Treated at LTFU Entry) analysis set consisted of all participants who converted to McDonald MS (2005) during the ITP, completed ITP 96-weeks and entered the LTFU. Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.24" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="2.19" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.25" spread="0.46"/>
                    <measurement group_id="O3" value="0.18" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.10" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions</title>
        <description>Number of CUA lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>LTFU: Baseline, Week 13, 24, 36 and 48</time_frame>
        <population>LTFU analysis set (No Treatment at LTFU Entry) was used. Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions</title>
          <description>Number of CUA lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>LTFU analysis set (No Treatment at LTFU Entry) was used. Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.03" spread="0.17"/>
                    <measurement group_id="O3" value="0.14" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.04" spread="0.21"/>
                    <measurement group_id="O3" value="0.18" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.13" spread="0.35"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.33" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ITP: Change From Baseline in Volume of T1 Gd-Enhanced Lesions</title>
        <description>Change in volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>ITP: Baseline, Week 96</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo). Here &quot;Number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; = participants evaluable at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Change From Baseline in Volume of T1 Gd-Enhanced Lesions</title>
          <description>Change in volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo). Here &quot;Number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; = participants evaluable at specified timepoint.</population>
          <units>cubic millimeters (mm^3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.97" spread="204.80"/>
                    <measurement group_id="O2" value="-126.64" spread="399.39"/>
                    <measurement group_id="O3" value="48.63" spread="239.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Point Estimate</param_type>
            <param_value>-1.700</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.200</ci_lower_limit>
            <ci_upper_limit>0.000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Point Estimate</param_type>
            <param_value>-28.600</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-117.300</ci_lower_limit>
            <ci_upper_limit>0.000</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLMP: Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions</title>
        <description>Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>OLMP: Baseline, Week 24, 48, 72 and 96</time_frame>
        <population>OLMP Analysis Set was used. Here &quot;Number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; = participants evaluable at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (OLMP)</title>
            <description>Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
        </group_list>
        <measure>
          <title>OLMP: Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions</title>
          <description>Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>OLMP Analysis Set was used. Here &quot;Number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; = participants evaluable at specified timepoint.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.06" spread="368.98"/>
                    <measurement group_id="O2" value="113.64" spread="248.74"/>
                    <measurement group_id="O3" value="136.61" spread="344.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.71" spread="26.35"/>
                    <measurement group_id="O2" value="3.48" spread="16.70"/>
                    <measurement group_id="O3" value="9.14" spread="55.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.22" spread="19.75"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="39.00" spread="188.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.52" spread="377.85"/>
                    <measurement group_id="O2" value="56.86" spread="160.83"/>
                    <measurement group_id="O3" value="25.85" spread="96.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330.20" spread="442.02"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="22.51" spread="87.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-87.30" spread="379.50"/>
                    <measurement group_id="O2" value="-120.04" spread="250.42"/>
                    <measurement group_id="O3" value="-134.67" spread="343.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-106.82" spread="415.70"/>
                    <measurement group_id="O2" value="-146.62" spread="298.86"/>
                    <measurement group_id="O3" value="-116.06" spread="429.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.00" spread="600.82"/>
                    <measurement group_id="O2" value="-155.91" spread="341.97"/>
                    <measurement group_id="O3" value="-192.24" spread="439.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275.83" spread="360.07"/>
                    <measurement group_id="O2" value="-391.93" spread="523.92"/>
                    <measurement group_id="O3" value="-247.76" spread="593.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions</title>
        <description>Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>LTFU: Baseline, Week 13, 24 and 36</time_frame>
        <population>LTFU analysis set (Treated at LTFU Entry) was used. Here &quot;Number analyzed&quot; = participants evaluable at specified timepoint for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions</title>
          <description>Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>LTFU analysis set (Treated at LTFU Entry) was used. Here &quot;Number analyzed&quot; = participants evaluable at specified timepoint for this outcome measure.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="79.43" spread="143.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="20.56" spread="70.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="25.23" spread="66.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="-63.83" spread="147.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="-32.25" spread="113.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="-58.93" spread="85.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions</title>
        <description>Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>LTFU: Baseline, Week 13, 24, 36 and 48</time_frame>
        <population>LTFU analysis set (No Treatment at LTFU Entry) was used. Here &quot;Number analyzed&quot; = participants evaluable at specified timepoint for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions</title>
          <description>Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>LTFU analysis set (No Treatment at LTFU Entry) was used. Here &quot;Number analyzed&quot; = participants evaluable at specified timepoint for this outcome measure.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="4.45" spread="21.25"/>
                    <measurement group_id="O3" value="27.79" spread="76.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="7.34" spread="27.76"/>
                    <measurement group_id="O3" value="17.43" spread="57.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="57.22" spread="127.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="57.22" spread="99.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.38" spread="1.32"/>
                    <measurement group_id="O3" value="-17.95" spread="41.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="-2.48" spread="9.60"/>
                    <measurement group_id="O3" value="-20.60" spread="57.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="-5.31" spread="14.06"/>
                    <measurement group_id="O3" value="-31.48" spread="54.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ITP: Changes From Baseline in Volume of T2 Lesions</title>
        <description>Change in volume of T2 lesions from baseline was measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>ITP: Baseline, Week 48 and 96</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo). Here &quot;Number analyzed&quot; = participants evaluable at specified timepoint for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Changes From Baseline in Volume of T2 Lesions</title>
          <description>Change in volume of T2 lesions from baseline was measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo). Here &quot;Number analyzed&quot; = participants evaluable at specified timepoint for this outcome measure.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="206"/>
                    <count group_id="O3" value="206"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3825.73" spread="5093.52"/>
                    <measurement group_id="O2" value="3435.22" spread="5184.12"/>
                    <measurement group_id="O3" value="3436.69" spread="4613.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="143"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-654.20" spread="2061.85"/>
                    <measurement group_id="O2" value="-828.97" spread="3513.04"/>
                    <measurement group_id="O3" value="-29.57" spread="2581.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1237.44" spread="2718.76"/>
                    <measurement group_id="O2" value="-1605.63" spread="2889.61"/>
                    <measurement group_id="O3" value="-886.39" spread="2955.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLMP: Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions</title>
        <description>Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>OLMP: Baseline, Week 48 and 96</time_frame>
        <population>OLMP Analysis Set was used. Here &quot;Number analyzed&quot; = participants evaluable at specified timepoint for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (OLMP)</title>
            <description>Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
        </group_list>
        <measure>
          <title>OLMP: Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions</title>
          <description>Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>OLMP Analysis Set was used. Here &quot;Number analyzed&quot; = participants evaluable at specified timepoint for this outcome measure.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398.88" spread="1102.27"/>
                    <measurement group_id="O2" value="630.70" spread="1707.24"/>
                    <measurement group_id="O3" value="1019.30" spread="2872.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="767.66" spread="1875.86"/>
                    <measurement group_id="O2" value="458.13" spread="984.12"/>
                    <measurement group_id="O3" value="508.97" spread="1159.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2606.15" spread="5542.81"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="647.17" spread="1345.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="523.27" spread="2065.54"/>
                    <measurement group_id="O2" value="-20.20" spread="2025.21"/>
                    <measurement group_id="O3" value="-77.67" spread="1760.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2245.18" spread="5810.53"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="255.39" spread="1352.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T2 Lesions</title>
        <description>Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>LTFU: Baseline (Day 1)</time_frame>
        <population>LTFU analysis set (Treated at LTFU Entry) was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T2 Lesions</title>
          <description>Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>LTFU analysis set (Treated at LTFU Entry) was used.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1217.53" spread="1991.21"/>
                    <measurement group_id="O2" value="587.79" spread="1491.20"/>
                    <measurement group_id="O3" value="702.30" spread="1254.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions</title>
        <description>Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>LTFU analysis set (No Treatment at LTFU Entry) was used. Here &quot;Number analyzed&quot; = participants evaluable at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions</title>
          <description>Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>LTFU analysis set (No Treatment at LTFU Entry) was used. Here &quot;Number analyzed&quot; = participants evaluable at specified timepoint.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1402.08" spread="1799.96"/>
                    <measurement group_id="O2" value="962.26" spread="1026.99"/>
                    <measurement group_id="O3" value="1407.75" spread="1890.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-969.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ITP: Number of T1 Hypointense Lesions</title>
        <description>Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>ITP: Baseline, Week 48 and 96</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo). Here &quot;Number analyzed&quot; = participants evaluable at specified timepoint for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Number of T1 Hypointense Lesions</title>
          <description>Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo). Here &quot;Number analyzed&quot; = participants evaluable at specified timepoint for this outcome measure.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="206"/>
                    <count group_id="O3" value="206"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="11.7"/>
                    <measurement group_id="O2" value="7.3" spread="12.2"/>
                    <measurement group_id="O3" value="7.0" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.39" spread="12.60"/>
                    <measurement group_id="O2" value="6.95" spread="12.86"/>
                    <measurement group_id="O3" value="7.07" spread="8.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.35" spread="8.14"/>
                    <measurement group_id="O2" value="3.82" spread="6.89"/>
                    <measurement group_id="O3" value="5.06" spread="6.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLMP: Number of T1 Hypointense Lesions</title>
        <description>Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>OLMP: Baseline, Week 48 and 96</time_frame>
        <population>OLMP Analysis Set included all participants who received at least 1 dose of study medication, converted to CDMS in the ITP period, entered the OLMP and received at least 1 dose of OLMP study drug (Rebif). Here &quot;Number analyzed&quot; = participants evaluable at specified timepoint for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (OLMP)</title>
            <description>Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
        </group_list>
        <measure>
          <title>OLMP: Number of T1 Hypointense Lesions</title>
          <description>Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>OLMP Analysis Set included all participants who received at least 1 dose of study medication, converted to CDMS in the ITP period, entered the OLMP and received at least 1 dose of OLMP study drug (Rebif). Here &quot;Number analyzed&quot; = participants evaluable at specified timepoint for this outcome measure.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="2.22"/>
                    <measurement group_id="O2" value="2.32" spread="9.52"/>
                    <measurement group_id="O3" value="1.45" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" spread="8.32"/>
                    <measurement group_id="O2" value="1.00" spread="2.85"/>
                    <measurement group_id="O3" value="0.74" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.84"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.47" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of T1 Hypointense Lesions</title>
        <description>Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>LTFU: Baseline (Day 1)</time_frame>
        <population>LTFU analysis set (Treated at LTFU Entry) analysis set consisted of all participants who converted to McDonald MS (2005) during the ITP, completed ITP 96-weeks and entered the LTFU.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of T1 Hypointense Lesions</title>
          <description>Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>LTFU analysis set (Treated at LTFU Entry) analysis set consisted of all participants who converted to McDonald MS (2005) during the ITP, completed ITP 96-weeks and entered the LTFU.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" spread="7.25"/>
                    <measurement group_id="O2" value="1.22" spread="3.31"/>
                    <measurement group_id="O3" value="2.24" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of T1 Hypointense Lesions</title>
        <description>Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>LTFU: Baseline, Week 48</time_frame>
        <population>LTFU analysis set (No Treatment at LTFU Entry) was used. Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of T1 Hypointense Lesions</title>
          <description>Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>LTFU analysis set (No Treatment at LTFU Entry) was used. Here &quot;Number analyzed&quot; signifies those participants who were evaluable at specified time point for this outcome measure.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.74" spread="8.21"/>
                    <measurement group_id="O2" value="3.53" spread="5.78"/>
                    <measurement group_id="O3" value="2.93" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ITP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions</title>
        <description>T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.</description>
        <time_frame>ITP: Baseline up to Week 96</time_frame>
        <population>The ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions</title>
          <description>T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.</description>
          <population>The ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLMP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions</title>
        <description>T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.</description>
        <time_frame>OLMP: Baseline up to Week 96</time_frame>
        <population>OLMP Analysis Set included all participants who received at least 1 dose of study medication, converted to CDMS in the ITP period, entered the OLMP and received at least 1 dose of OLMP study drug (Rebif).</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (OLMP)</title>
            <description>Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
        </group_list>
        <measure>
          <title>OLMP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions</title>
          <description>T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.</description>
          <population>OLMP Analysis Set included all participants who received at least 1 dose of study medication, converted to CDMS in the ITP period, entered the OLMP and received at least 1 dose of OLMP study drug (Rebif).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions</title>
        <description>T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.</description>
        <time_frame>LTFU: Baseline up to Week 48</time_frame>
        <population>LTFU analysis set (Treated at LTFU Entry) was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions</title>
          <description>T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.</description>
          <population>LTFU analysis set (Treated at LTFU Entry) was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions</title>
        <description>T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.</description>
        <time_frame>Baseline up to Week 48</time_frame>
        <population>LTFU analysis set (No Treatment at LTFU Entry) was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions</title>
          <description>T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.</description>
          <population>LTFU analysis set (No Treatment at LTFU Entry) was used.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ITP: Percentage of Participants With no New or Enlarging T2 Lesions</title>
        <description>T2 lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or enlarging T2 lesions were reported.</description>
        <time_frame>ITP: Baseline up to Week 96</time_frame>
        <population>The ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Percentage of Participants With no New or Enlarging T2 Lesions</title>
          <description>T2 lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or enlarging T2 lesions were reported.</description>
          <population>The ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9"/>
                    <measurement group_id="O2" value="35.1"/>
                    <measurement group_id="O3" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLMP: Percentage of Participants With no New or Enlarging T2 Lesions</title>
        <description>T2 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or enlarging T2 Lesions were reported.</description>
        <time_frame>OLMP: Baseline up to 96</time_frame>
        <population>OLMP Analysis Set included all participants who received at least 1 dose of study medication, converted to CDMS in the ITP period, entered the OLMP and received at least 1 dose of OLMP study drug (Rebif).</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (OLMP)</title>
            <description>Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
        </group_list>
        <measure>
          <title>OLMP: Percentage of Participants With no New or Enlarging T2 Lesions</title>
          <description>T2 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or enlarging T2 Lesions were reported.</description>
          <population>OLMP Analysis Set included all participants who received at least 1 dose of study medication, converted to CDMS in the ITP period, entered the OLMP and received at least 1 dose of OLMP study drug (Rebif).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions</title>
        <description>Enlarging T2 Lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no New or Enlarging T2 Lesions were reported.</description>
        <time_frame>Baseline up to Week 48</time_frame>
        <population>LTFU analysis set (Treated at LTFU Entry) was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions</title>
          <description>Enlarging T2 Lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no New or Enlarging T2 Lesions were reported.</description>
          <population>LTFU analysis set (Treated at LTFU Entry) was used.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions</title>
        <description>Enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no New or Enlarging T2 lesions were reported.</description>
        <time_frame>LTFU: Baseline up to Week 48</time_frame>
        <population>LTFU analysis set (No Treatment at LTFU Entry) was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions</title>
          <description>Enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no New or Enlarging T2 lesions were reported.</description>
          <population>LTFU analysis set (No Treatment at LTFU Entry) was used.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ITP: Percent Change From Baseline in Brain Volume</title>
        <description>Brain volume was measured by using magnetic resonance imaging (MRI) scans. Percent change from baseline in brain volume at Week 48 and 96 was reported.</description>
        <time_frame>ITP: Baseline, Week 48 and 96</time_frame>
        <population>The ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo). Here &quot;Number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; = participants evaluable at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Percent Change From Baseline in Brain Volume</title>
          <description>Brain volume was measured by using magnetic resonance imaging (MRI) scans. Percent change from baseline in brain volume at Week 48 and 96 was reported.</description>
          <population>The ITT population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo). Here &quot;Number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; = participants evaluable at specified timepoint.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.63"/>
                    <measurement group_id="O2" value="-0.48" spread="0.69"/>
                    <measurement group_id="O3" value="-0.33" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.80"/>
                    <measurement group_id="O2" value="-0.72" spread="0.73"/>
                    <measurement group_id="O3" value="-0.75" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLMP: Percent Change From Baseline in Brain Volume</title>
        <description>Brain volume was measured by using magnetic resonance imaging (MRI) scans. Percent change from baseline in brain volume at Week 48 and 96 was reported.</description>
        <time_frame>OLMP: Baseline, Week 48 and 96</time_frame>
        <population>OLMP Analysis Set was used. Here &quot;Number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; = participants evaluable at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (OLMP)</title>
            <description>Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (OLMP)</title>
            <description>Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
          </group>
        </group_list>
        <measure>
          <title>OLMP: Percent Change From Baseline in Brain Volume</title>
          <description>Brain volume was measured by using magnetic resonance imaging (MRI) scans. Percent change from baseline in brain volume at Week 48 and 96 was reported.</description>
          <population>OLMP Analysis Set was used. Here &quot;Number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; = participants evaluable at specified timepoint.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.98"/>
                    <measurement group_id="O2" value="-1.60" spread="1.40"/>
                    <measurement group_id="O3" value="-0.56" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="1.36"/>
                    <measurement group_id="O3" value="-1.31" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLMP: Number of Relapses</title>
        <description>Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.</description>
        <time_frame>Baseline up to Week 96</time_frame>
        <population>OLMP Analysis Set included all participants who received at least 1 dose of study medication, converted to CDMS in the ITP period, entered the OLMP and received at least 1 dose of OLMP study drug (Rebif).</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>OLMP: Number of Relapses</title>
          <description>Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.</description>
          <population>OLMP Analysis Set included all participants who received at least 1 dose of study medication, converted to CDMS in the ITP period, entered the OLMP and received at least 1 dose of OLMP study drug (Rebif).</population>
          <units>Relapses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.64"/>
                    <measurement group_id="O2" value="0.16" spread="0.37"/>
                    <measurement group_id="O3" value="0.55" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Relapses</title>
        <description>Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.</description>
        <time_frame>Baseline up to Week 48</time_frame>
        <population>LTFU analysis set (Treated at LTFU Entry) was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Relapses</title>
          <description>Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.</description>
          <population>LTFU analysis set (Treated at LTFU Entry) was used.</population>
          <units>Relapses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.06" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Relapses</title>
        <description>Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.</description>
        <time_frame>Baseline up to Week 48</time_frame>
        <population>LTFU analysis set (No Treatment at LTFU Entry) was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg, Rebif (LTFU)</title>
            <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Rebif (LTFU)</title>
            <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
          </group>
        </group_list>
        <measure>
          <title>LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Relapses</title>
          <description>Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.</description>
          <population>LTFU analysis set (No Treatment at LTFU Entry) was used.</population>
          <units>Relapses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.17"/>
                    <measurement group_id="O2" value="0.03" spread="0.17"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLMP: Annualized Relapse Rate</title>
        <description>The annualized relapse rate for each treatment group was the mean of the annualized relapse rates for all the participants in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25. Where, Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.</description>
        <time_frame>Baseline up to Week 96</time_frame>
        <population>OLMP Analysis Set included all participants who received at least 1 dose of study medication, converted to CDMS in the ITP period, entered the OLMP and received at least 1 dose of OLMP study drug (Rebif).</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>OLMP: Annualized Relapse Rate</title>
          <description>The annualized relapse rate for each treatment group was the mean of the annualized relapse rates for all the participants in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25. Where, Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.</description>
          <population>OLMP Analysis Set included all participants who received at least 1 dose of study medication, converted to CDMS in the ITP period, entered the OLMP and received at least 1 dose of OLMP study drug (Rebif).</population>
          <units>relapses per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.07" upper_limit="0.40"/>
                    <measurement group_id="O2" value="0.14" lower_limit="0.00" upper_limit="0.27"/>
                    <measurement group_id="O3" value="0.42" lower_limit="0.28" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLMP: Percentage of Relapse-Free Participants</title>
        <description>Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Percentage of relapse-free participants were reported.</description>
        <time_frame>Baseline up to Week 96</time_frame>
        <population>OLMP Analysis Set included all participants who received at least 1 dose of study medication, converted to CDMS in the ITP period, entered the OLMP and received at least 1 dose of OLMP study drug (Rebif). Here &quot;Number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>OLMP: Percentage of Relapse-Free Participants</title>
          <description>Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Percentage of relapse-free participants were reported.</description>
          <population>OLMP Analysis Set included all participants who received at least 1 dose of study medication, converted to CDMS in the ITP period, entered the OLMP and received at least 1 dose of OLMP study drug (Rebif). Here &quot;Number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ITP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs</title>
        <description>An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. Number of Participants with TEAEs and serious TEAEs were reported.</description>
        <time_frame>ITP: Baseline up to Week 96</time_frame>
        <population>Safety analysis set included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo) and had at least one safety assessment during the ITP.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg (ITP)</title>
            <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (ITP)</title>
            <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>ITP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs</title>
          <description>An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. Number of Participants with TEAEs and serious TEAEs were reported.</description>
          <population>Safety analysis set included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo) and had at least one safety assessment during the ITP.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="168"/>
                    <measurement group_id="O3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>ITP: Baseline up to 96 weeks; OLMP: Baseline up to 96 weeks; LTFU: Baseline up to 48 weeks</time_frame>
      <desc>ITP Safety analysis set(SAF). OLMP SAF: participants who received atleast 1dose of ITP study drug, converted to CDMS in ITP, entered OLMP and received atleast 1dose of OLMP study drug. LTFU (Treated)SAF: Participants who converted to McDonald MS(2005)during ITP, completed ITP 96-weeks and entered LTFU and treated with cladribine when entering LTFU. LTFU(Not-Treated) SAF:Participants who completed ITP 96-weeks and entered LTFU for safety follow-up and didn't receive study drug upon entry to LTFU.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cladribine 5.25 mg/kg (ITP)</title>
          <description>Cladribine tablets administered as cumulative dose of 0.875 milligrams per kilograms (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.</description>
        </group>
        <group group_id="E2">
          <title>Cladribine 3.5 mg/kg (ITP)</title>
          <description>Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (ITP)</title>
          <description>Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.</description>
        </group>
        <group group_id="E4">
          <title>Cladribine 5.25 mg/kg, Rebif (OLMP)</title>
          <description>Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
        </group>
        <group group_id="E5">
          <title>Cladribine 3.5 mg/kg, Rebif (OLMP)</title>
          <description>Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
        </group>
        <group group_id="E6">
          <title>Placebo, Rebif (OLMP)</title>
          <description>Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.</description>
        </group>
        <group group_id="E7">
          <title>Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
          <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period . Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
        </group>
        <group group_id="E8">
          <title>Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
          <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period . Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
        </group>
        <group group_id="E9">
          <title>Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)</title>
          <description>Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period . Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
        </group>
        <group group_id="E10">
          <title>Cladribine 5.25 mg/kg, Rebif (LTFU)</title>
          <description>Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
        </group>
        <group group_id="E11">
          <title>Cladribine 3.5 mg/kg, Rebif (LTFU)</title>
          <description>Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
        </group>
        <group group_id="E12">
          <title>Placebo, Rebif (LTFU)</title>
          <description>Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperprolactinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Tonsillar neoplasm benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Bartholin's cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Tracheal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="116" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="41" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastrointestinal toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Radicular cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholin's cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Communication Center</name_or_title>
      <organization>Merck KGaA, Darmstadt, Germany</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@emdgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

